Drzewiecka, M.; Jaśniak, D.; Barszczewska-Pietraszek, G.; Czarny, P.; Kobrzycka, A.; Wieczorek, M.; Radek, M.; Szemraj, J.; Skorski, T.; Śliwiński, T.
Class I HDAC Inhibition Leads to a Downregulation of FANCD2 and RAD51, and the Eradication of Glioblastoma Cells. J. Pers. Med. 2023, 13, 1315.
https://doi.org/10.3390/jpm13091315
AMA Style
Drzewiecka M, Jaśniak D, Barszczewska-Pietraszek G, Czarny P, Kobrzycka A, Wieczorek M, Radek M, Szemraj J, Skorski T, Śliwiński T.
Class I HDAC Inhibition Leads to a Downregulation of FANCD2 and RAD51, and the Eradication of Glioblastoma Cells. Journal of Personalized Medicine. 2023; 13(9):1315.
https://doi.org/10.3390/jpm13091315
Chicago/Turabian Style
Drzewiecka, Małgorzata, Dominika Jaśniak, Gabriela Barszczewska-Pietraszek, Piotr Czarny, Anna Kobrzycka, Marek Wieczorek, Maciej Radek, Janusz Szemraj, Tomasz Skorski, and Tomasz Śliwiński.
2023. "Class I HDAC Inhibition Leads to a Downregulation of FANCD2 and RAD51, and the Eradication of Glioblastoma Cells" Journal of Personalized Medicine 13, no. 9: 1315.
https://doi.org/10.3390/jpm13091315
APA Style
Drzewiecka, M., Jaśniak, D., Barszczewska-Pietraszek, G., Czarny, P., Kobrzycka, A., Wieczorek, M., Radek, M., Szemraj, J., Skorski, T., & Śliwiński, T.
(2023). Class I HDAC Inhibition Leads to a Downregulation of FANCD2 and RAD51, and the Eradication of Glioblastoma Cells. Journal of Personalized Medicine, 13(9), 1315.
https://doi.org/10.3390/jpm13091315
